Patents Assigned to MEDSHINE DISCOVERY INC.
  • Uracil compound as c-MET/AXL inhibitor
    Patent number: 11623923
    Abstract: Provided are a uracil compound represented by Formula (IV) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition of the same. Also provided is a use thereof as a c-MET/AXL inhibitor in preparing a c-MET/AXL-inhibiting drug or a drug for treating a tumor.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: April 11, 2023
    Assignee: MEDSHINE DISCOVERY, INC.
    Inventors: Jinping Li, Xiongbin Xu, Gang Li, Lihong Hu, Charles Z. Ding, Yaling Zhou, Guoping Hu, Jian Li, Shuhui Chen
  • Crystal form as inhibitor of ACC1 and ACC2, and preparation method therefor and use thereof
    Patent number: 11578081
    Abstract: Disclosed are a crystal form (I) as an inhibitor of ACC1 and ACC2, a preparation method therefor, and the use thereof in the preparation of a drug as an inhibitor of ACC1 and ACC2.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: February 14, 2023
    Assignees: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD., MEDSHINE DISCOVERY INC.
    Inventors: Fei Hong, Jinming Huang, Jinxia Lin, Yichao Zhuang, Zhiyi Luo, Xiaoping Zheng, Zhigan Jiang, Haiying He
  • Anti-HBVtetrahydroisoxazolo[4,3-c]pyridine compounds
    Patent number: 11572372
    Abstract: Disclosed are a class of anti-HBV tetrahydroisoxazolo[4,3-c]pyridine compounds and pharmaceutically acceptable salts thereof or isomers thereof, the compounds being represented by the formula (I).
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: February 7, 2023
    Assignee: Medshine Discovery Inc.
    Inventors: Lifang Wu, Fei Sun, Jinhua Du, Charles Z. Ding, Shuhui Chen, Xiquan Zhang, Hongjiang Xu, Ling Yang
  • CRYSTAL FORM AS INHIBITOR OF ACC1 AND ACC2, AND PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20230034132
    Abstract: Disclosed are a crystal form (I) as an inhibitor of ACC1 and ACC2, a preparation method therefor, and the use thereof in the preparation of a drug as an inhibitor of ACC1 and ACC2.
    Type: Application
    Filed: December 4, 2020
    Publication date: February 2, 2023
    Applicants: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD., MEDSHINE DISCOVERY INC.
    Inventors: Fei HONG, Jinming HUANG, Jinxia LIN, Yichao ZHUANG, Zhiyi LUO, Xiaoping ZHENG, Zhigan JIANG, Haiying HE
  • Pyrazole compounds as LSD1 inhibitors and applications thereof
    Patent number: 11524941
    Abstract: Disclosed are a class of pyrazole compounds and applications thereof in the preparation of a medicament for treating related diseases. Specifically, related are a compound represented by formula (II) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 30, 2021
    Date of Patent: December 13, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Lingyun Wu, Lele Zhao, Jianjun Sun, Zhen Zhan, Shuhui Chen
  • CRYSTAL FORM OF BENZIMIDAZOLE-2-ONE COMPOUND, SOLVATE THEREOF, CRYSTAL FORM OF SOLVATE THEREOF, AND PREPARATION METHOD THEREOF
    Publication number: 20220372001
    Abstract: A crystal form of compound 1, a solvate thereof, a crystal form of the solvate thereof, and a preparation method therefor. Further comprised is an application of the crystal forms in the preparation of a medicament for treating diseases related to TNF?.
    Type: Application
    Filed: July 3, 2020
    Publication date: November 24, 2022
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Maoyi LEI, Yunfu LUO
  • Crystal and salt forms of tricyclic compound and preparation process thereof
    Patent number: 11465995
    Abstract: Provided are a crystal form of a tricyclic compound and a preparation process thereof. Also provided is an application of the crystal form in preparing a drug for treating a disease related to a sphingosine-1-phosphate subtype 1 (S1P1) receptor.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: October 11, 2022
    Assignee: Medshine Discovery Inc.
    Inventors: Peng Zhang, Weidong Li, Lingyun Wu
  • Bicylic compound acting as an inhibitor
    Patent number: 11466024
    Abstract: A bicyclic compound acting as a ROR? inhibitor. Provided are a compound of formula (I) or a pharmaceutically acceptable salt thereof, the compound having a structure as represented by formula (I-A) or formula (I-B). The provided compound of formula (I-A) or formula (I-B) or pharmaceutically acceptable salt thereof has good ROR? inhibitory activities, being expected to be used for treating diseases mediated by ROR? receptors in a mammal.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: October 11, 2022
    Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Medshine Discovery Inc.
    Inventors: Kevin X Chen, Kai Zhou, Yanxin Yu, Boyu Hu, Linghui Wu, Xiaoyuan Chen, Jiangfeng Lin, Haomin Chen, Xiangjian Wang, Xiquan Zhang, Xin Tian, Hongjiang Xu
  • Monocyclic ?-lactam compound for treating bacterial infection
    Patent number: 11459323
    Abstract: Disclosed are a class of new monocyclic ?-lactam compounds, an isomer thereof or pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the compounds, and the use of same in preparing drugs for treating diseases associated with bacterial infection. Specifically disclosed are the compounds as shown in formula (I?) and formula (II?), isomers thereof or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: October 4, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Lianghu Gu, Wei Luo, Zhigang Huang, Charles Z. Ding, Cheng Li, Shuhui Chen
  • Pyridone-pyrimidine derivative acting as KRASG12C mutein inhibitor
    Patent number: 11453667
    Abstract: Provided are a class of KRAS G12C mutein inhibitors, which relate in particular to a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: September 27, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Yaxian Cai, Zhaobing Xu, Hailong Yang, Shiqi Han, Guoping Hu, Lihong Hu, Charles Z. Ding, Jian Li, Shuhui Chen
  • COMPOUND AS PORCUPINE INHIBITOR AND USE THEREOF
    Publication number: 20220281873
    Abstract: Disclosed is a class of porcupine inhibitors, specifically a compound as represented by formula (I), and a pharmaceutically acceptable salt or an isomer thereof.
    Type: Application
    Filed: July 8, 2020
    Publication date: September 8, 2022
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Xiongbin XU, Yi CHEN, Cailin WANG, Ru FENG, Wen JIANG, Lingyun WU, Jian LI, Shuhui CHEN
  • LSD1 inhibitor and preparation method and application thereof
    Patent number: 11433053
    Abstract: A cyclopropylamine compound as a lysine-specific demethylase 1 (LSD1) inhibitor. Particularly, the present invention relates to a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. The present invention also provides an application of the same in preparing a drug for treating an LSD1-related disease.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: September 6, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Lingyun Wu, Li Zhang, Lele Zhao, Jianjun Sun, Zhaoguo Chen, Jian Li, Shuhui Chen
  • QUINAZOLINE AND CINNOLINE DERIVATIVES AS DNA-PK INHIBITOR
    Publication number: 20220267310
    Abstract: Disclosed in the present invention are a compound as represented by formula (I), and an isomer or pharmaceutically acceptable salt thereof, and disclosed is an application thereof in preparing drugs for treating DNA-PK inhibitor-related diseases.
    Type: Application
    Filed: June 24, 2020
    Publication date: August 25, 2022
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Kevin X Chen, Zhaoguo Chen, Li Zhang, Boyu Hu, Shuhui Chen
  • CRYSTAL FORM AND SALT OF QUINAZOLINE COMPOUND AND PREPARATION METHOD THEREOF
    Publication number: 20220242851
    Abstract: The present invention relates to a crystal form and a salt of a compound serving as a Pan-HER tyrosine kinase inhibitor and a preparation method therefor, and also use thereof in the preparation of a medicament for treating solid tumors.
    Type: Application
    Filed: June 19, 2020
    Publication date: August 4, 2022
    Applicants: SHENZHEN JINRUI FOUNDATION BIOTECH CO., LTD, MEDSHINE DISCOVERY INC.
    Inventors: Kevin X. CHEN, Li ZHANG, Kai ZHOU, Yanxin YU, Boyu HU, Huiyu ZHANG
  • BICYCLIC COMPOUND AS RIP-1 KINASE INHIBITOR AND APPLICATION THEREOF
    Publication number: 20220242877
    Abstract: A compound represented by formula (I), isomers or pharmaceutically acceptable salts thereof, and application thereof in the preparation of drugs for treating diseases related to RIP-1 (receptor interacting protein) kinase.
    Type: Application
    Filed: May 29, 2020
    Publication date: August 4, 2022
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Wei WEI, Peng LI, Haiying HE, Shuhui CHEN
  • PYRAZOLOPYRIDINE COMPOUND AS RET INHIBITOR AND APPLICATION THEREOF
    Publication number: 20220220104
    Abstract: Disclosed is a series of pyrazolopyridine compounds, and application thereof in the preparation of RET kinase inhibitors for treatment. Specifically disclosed is the compound represented by formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 3, 2020
    Publication date: July 14, 2022
    Applicants: GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY, MEDSHINE DISCOVERY INC.
    Inventors: Jiansong WANG, Zhengxia CHEN, Zhibo LUO, Meibi DAI, Yang ZHANG, Shuhui CHEN, Yingxia BAO, Wei WANG, Zhoufan XIE
  • Heterocyclic compound as CSF-1R inhibitor and use thereof
    Patent number: 11384065
    Abstract: The present invention relates to a class of isoindolinone derivatives and use thereof in the preparation of a medicament for treating diseases associated with a novel colony stimulating factor 1 receptor (CSF-1R) inhibitor. In particular, the present invention relates to a compound of formula (I) and a pharmaceutically acceptable salt thereof or a stereoisomer thereof.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: July 12, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Wenyuan Qian, Chundao Yang, Guanghai Xu, Jie Li, Jian Li, Shuhui Chen
  • Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors
    Patent number: 11377444
    Abstract: Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: July 5, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Kevin X Chen, Zhaoguo Chen, Li Zhang, Yanxin Yu, Kai Zhou, Boyu Hu, Xiaofei Wang, Guoping Hu, Jian Li, Shuhui Chen
  • NITROGEN-CONTAINING SPIRO DERIVATIVE AS RET INHIBITOR
    Publication number: 20220204507
    Abstract: Disclosed are a series of compounds with a nitrogen-containing spiro structure and an application thereof in the preparation of an RET kinase inhibitor. Specifically, disclosed is a compound as shown in formula (II) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 3, 2020
    Publication date: June 30, 2022
    Applicants: GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY, MEDSHINE DISCOVERY INC.
    Inventors: Jiansong WANG, Zhifei FU, Zhibo LUO, Miaorong LUO, Yang ZHANG, Yalei CAI, Wu ZHU, Jian LI, Shuhui CHEN, Yingxia BAO, Wei WANG, Zhoufan XIE
  • MACROCYCLIC DERIVATIVES ACTING AS XIA FACTOR INHIBITOR
    Publication number: 20220204508
    Abstract: Disclosed are a class of macrocyclic derivatives, a preparation method therefor, a pharmaceutical composition containing the derivatives, and the use thereof as therapeutic agents, particularly as XIa factor inhibitors and in the preparation of a drug for treating and preventing thromboembolisms and other diseases. Particularly disclosed are compounds shown by formula (I), an isomer thereof and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 15, 2020
    Publication date: June 30, 2022
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Yaxian Cai, Xiaobing Yan, Ting Wang, Chengde Wu, Charles Z. Ding, Shuhui Chen